Evidence map›Paper›PMID 34548246›Full record

Trial reportTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021

Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - A case series.

Johanna Erber, Johannes R Wiessner, Christina Huberle, Jochen Schneider, Hrvoje Mijočević, Doris von Bomhard, Peter Luppa, Roland M Schmid, Sebastian Rasch, Tobias Lahmer

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johanna ErberTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Johannes R WiessnerTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Christina HuberleTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Jochen SchneiderTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Hrvoje MijočevićTechnical University of Munich, School of Medicine, Institute of Virology, Munich, Germany.
Doris von BomhardTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Institute of Clinical Chemistry and Pathobiochemistry, 81675, Munich, Germany.
Peter LuppaTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Institute of Clinical Chemistry and Pathobiochemistry, 81675, Munich, Germany.
Roland M SchmidTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Sebastian RaschTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.
Tobias LahmerTechnical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany. Electronic address: Tobias.Lahmer@mri.tum.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of convalescent plasma therapy (CPT) on clinical courses of B-cell-sufficient and B-cell-depleted patients with life-threatening COVID-19. PATIENTS AND

methodsIn this case series, we retrospectively analysed clinical, laboratory and cardiopulmonary parameters of six patients with life-threatening COVID-19 receiving convalescent plasma (CP) as rescue therapy between April 11, 2020 to October 10, 2020. Clinical and laboratory parameters before and after transfusion were compared in two B-cell-depleted patients and four B-cell sufficient patients (control group).

resultsBoth B-cell-depleted patients cleared SARS-CoV-2 virus and survived, while all other patients died within 14 days from intervention despite maximal therapeutic efforts. D-dimer levels increased in both cohorts subsequent to CPT. In control patients, mean Interleukin-6 increased and platelet levels decreased as opposed to decreasing and stable levels in B-cell-depleted patients, respectively. Control patients required increased doses of vasopressor compared to decreasing doses in B-cell depleted patients subsequent to CPT. PO

conclusionUse of CP in late stages of life-threatening COVID-19 should be used with caution but may be beneficial in B-cell-depleted patients. Further studies are necessary to assess factors predicting potential therapeutic benefits as well as possible hazards.

Indexed as

B-LymphocytesLymphocyte DepletionSARS-CoV-2AdultAgedCOVID-19COVID-19 SerotherapyDisease-Free SurvivalFemaleHumansImmunization, PassiveMaleMiddle AgedRetrospective StudiesSurvival RateB-cell depletionConvalescent plasmaLife-threatening COVID-19SARS-CoV-2

Identifiers

PMID34548246
PMCPMC8447834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.